Victoza (liraglutide) was Novo Nordisk’s first GLP-1 receptor agonist, approved for type 2 diabetes in 2010, and although newer drugs like Ozempic have overshadowed it, Victoza remains a reliable option with a retail price around $1,050 to $1,200 per month. The Victoza patient assistance program, part of the broader Novo Nordisk Patient Assistance Program (NPAP), provides free Victoza to qualifying uninsured patients earning up to 400% of the federal poverty level. The Victoza patient assistance program is especially relevant now that liraglutide is nearing patent expiration and generic competition is imminent. Our healthcare costs guide covers more prescription savings strategies.
What the Victoza Patient Assistance Program Provides
The Novo Nordisk PAP ships free Victoza to qualifying patients or to their prescriber’s office every 90 to 120 days. Approved patients receive the medication in prefilled multidose pens (3-pack) at no cost, with no shipping or administrative fees. The program is funded directly by Novo Nordisk as part of its corporate patient assistance commitments, not through a third-party foundation.
Besides Victoza, the same NPAP application covers Novo Nordisk’s other GLP-1 drugs (Ozempic, Rybelsus, Saxenda, Wegovy) and insulin products (Tresiba, Levemir, NovoLog, Fiasp, and older human insulins). If your doctor prescribes more than one Novo Nordisk product, you can apply for all of them on a single form.
Who Qualifies for the Victoza Patient Assistance Program
NPAP uses four core eligibility criteria, and applicants must meet all of them. First, you must be a US citizen or legal resident with a valid prescription from a licensed US physician. Second, your total household income must be at or below 400% of the federal poverty level, which in 2026 is approximately $60,240 for a single-person household and $124,800 for a family of four per HHS guidelines.
Third, you must be uninsured, or if you have Medicare Part D, you must have spent at least $1,000 out of pocket on prescription drugs in the current calendar year and not be eligible for Extra Help (the Medicare Low-Income Subsidy). Fourth, commercially insured patients are not eligible for NPAP; Novo Nordisk directs them to the NovoCare Savings Card instead. Medicaid enrollees are also excluded because Medicaid already covers Victoza.
How to Apply for the Victoza Patient Assistance Program
The application process takes two to four weeks from submission to first medication shipment. Begin at NovoCare.com, select the Patient Assistance Program section, and download the application form, or call 1-866-310-7549 to request a paper copy by mail. Complete the patient section with demographic information, household size, income, and insurance status. Sign the authorization for income verification.
Your prescribing physician completes the prescriber section with your type 2 diabetes diagnosis, the Victoza prescription details (dose and quantity), and signature. Both sections must be submitted together. Include proof of income, typically a copy of your most recent IRS Form 1040 or three recent pay stubs. Patients with no documentable income can submit a signed attestation letter explaining their financial situation.
Submit the completed application by fax to 1-866-441-4190, by mail to the address on the form, or through the NovoCare secure upload portal. Novo Nordisk reviews the application and notifies you and your prescriber of the decision. Approved patients receive their first shipment within roughly three weeks.
Alternatives If You Don’t Qualify for NPAP
Commercially insured patients excluded from NPAP should use the NovoCare Savings Card, which drops Victoza copays to as little as $25 per month for eligible patients with commercial coverage. Enroll at NovoCare.com. The card applies at most retail pharmacies when your prescription is processed through commercial insurance first.
Medicare Part D enrollees cannot use the NovoCare Savings Card because of federal anti-kickback rules, but they benefit from the 2025-2026 Part D out-of-pocket cap of $2,100, which includes Victoza spending. The new Medicare Prescription Payment Plan (M3P) also allows Part D patients to spread that $2,100 over 12 monthly installments at no extra cost per CMS.
GoodRx and Cash-Pay Options for Victoza
GoodRx Victoza coupons cut the retail price by roughly 5% to 15%, bringing a monthly supply to about $950 to $1,075. This is a meaningful dollar amount, but it pales compared to NPAP’s $0 program for qualifying patients. SingleCare and WellRx offer similar discounts within a few dollars of GoodRx.
Liraglutide (the active ingredient in Victoza) went off-patent in 2023, and the FDA approved the first generic liraglutide in mid-2024. As of 2026, generic liraglutide is beginning to appear at select pharmacies at roughly 30% to 50% lower than branded Victoza. If cost is a concern, ask your prescriber to write for generic liraglutide rather than branded Victoza when available. Our NovoCare PAP guide and Tresiba PAP guide cover parallel Novo Nordisk programs.
What to Do If You’re Denied for NPAP
Patients denied for NPAP typically fall into one of three categories: household income above 400% FPL, commercial insurance coverage, or Medicare Part D without the required $1,000 out-of-pocket spending. For each, the alternative is different. Commercially insured patients should use the NovoCare Savings Card. Medicare Part D patients should wait until they have spent $1,000 out of pocket and reapply, or enroll in the M3P payment plan.
Patients above 400% FPL and uninsured have the hardest time. Options include Novo Nordisk’s cash pricing program for insulins (though this does not cover Victoza), GoodRx discount coupons, and nonprofit foundations like the Patient Access Network Foundation (panfoundation.org) that maintain disease-specific diabetes funds. NeedyMeds.org aggregates patient assistance resources across all drugs and manufacturers.
Frequently Asked Questions
Is the Victoza patient assistance program really free?
Yes. Qualifying patients receive Victoza at no cost, with no application fees or shipping charges. The program is funded directly by Novo Nordisk through its corporate patient assistance commitments.
How long does it take to get approved for the Victoza PAP?
Most complete applications are processed within two to four weeks. Incomplete applications or missing documentation can extend the timeline. Call 1-866-310-7549 if you have not heard back within 30 days.
Can I get Victoza for free if I have Medicare?
Medicare Part D patients can apply to NPAP if they have spent at least $1,000 out of pocket on prescriptions in the current year and are not enrolled in Extra Help. Most Medicare patients are better served by the 2026 Part D $2,100 out-of-pocket cap and the M3P payment plan.
Is generic liraglutide cheaper than the Victoza patient assistance program?
Generic liraglutide is typically $500 to $800 per month at retail, while NPAP Victoza is free for qualifying patients. NPAP remains cheaper for those who qualify. Generic liraglutide is a good option for patients above 400% FPL who do not qualify for NPAP.
Does the Victoza patient assistance program cover Saxenda?
Yes. Saxenda is also liraglutide (same active ingredient as Victoza, different dose and indication for weight management) and is covered under the same NPAP. You can apply for Victoza, Saxenda, or both on a single application.
The Bottom Line
The Victoza patient assistance program, part of the Novo Nordisk Patient Assistance Program, provides free Victoza to uninsured and underinsured patients earning up to 400% of the federal poverty level. Apply at NovoCare.com or call 1-866-310-7549, coordinate with your prescribing physician, and submit proof of income. Commercially insured patients should use the NovoCare Savings Card instead, Medicare patients should use the 2026 Part D cap and M3P payment plan, and patients above 400% FPL can ask for generic liraglutide as a cheaper alternative to branded Victoza.